Navigation Links
Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
Date:4/16/2009

WILMINGTON, Del., April 16 /PRNewswire-FirstCall/ -- On 16 April 2009, the US District Court for the District of New Jersey granted AstraZeneca's request for a temporary restraining order, barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT RESPULES until further order of the court. On 27 April 2009, the court will commence a hearing to determine whether the injunction should be continued.

On 30 March 2009, the US FDA granted approval for a generic version of AstraZeneca's PULMICORT RESPULES (budesonide inhalation suspension) to Apotex. AstraZeneca then filed suit following Apotex's indication of intent to market a generic version of AstraZeneca's PULMICORT RESPULES in the US prior to the expiration of AstraZeneca's patents.

AstraZeneca has full confidence in the strength of its intellectual property rights protecting PULMICORT RESPULES and will continue to vigorously defend and enforce its intellectual property.

Patents covering PULMICORT RESPULES expire in 2018 with pediatric exclusivity extending to 2019.

About PULMICORT RESPULES

PULMICORT RESPULES is a preventive, maintenance asthma medicine indicated for use in children 12 months to 8 years of age in the United States. Full-year US sales for PULMICORT in 2008 totalled $982 million, about 90 percent of which is accounted for by PULMICORT RESPULES.

About AstraZeneca

AstraZeneca (NYSE: AZN) is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
2. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
3. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
4. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
5. Massachusetts State Court Hears Suit by Breastfeeding Mother on Medical Licensing Exam
6. Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research
7. Filing for Reconsideration/Press Conference ACUNA v. TURKISH, Historic Informed Consent Abortion Case to the New Jersey Supreme Court
8. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
9. NBME Appeals Massachusetts Judges Reversal of Lower Court in Suit for Extra Break Time During Medical Licensing Exam
10. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
11. ALLs Judie Brown: Supreme Court is Wrong on Contraception Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... ... with blogs, groups, forums, photos and videos , ... Norfolk, Va. (PRWEB) November 2, 2009 -- HealthCareerWeb.com, a full service healthcare ... online health care jobs section with its medical professional network . , ...
... 2 STANDUP FOR KIDS has been chosen by STAR ... businesses are being asked to join forces for charity ... for November,s National Homeless Youth Awareness Month. Local business ... OF THE NEIGHBORHOOD, are displaying posters and encouraging their customers ...
... On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. ... (Nasdaq and MTA: CTIC) management team will host a conference ... , , Conference Call Numbers, ... p.m. Central European/5:30 a.m. Pacific Time, 1-877-941-6010 ...
... , the journal of the American Academy of Ophthalmology ... surgery is likely to benefit patients with age-related macular ... a clinical trial showing that the steroid triamcinolone may ... when standard treatment fails, and on the public,s use ...
... Nov. 1 Schering-Plough Corporation (NYSE: SGP ) ... with boceprevir combination therapy in patients with chronic hepatitis ... were presented at the American Association for the Study ... 30-Nov. 3. , Boceprevir is an investigational ...
... body fat means greater survival odds, researcher says , SUNDAY, Nov. ... are much more likely to die than other people on dialysis, ... study has found. , Researchers measured body fat percentage in 671 ... rate for people with less than 10 percent body fat was ...
Cached Medicine News:Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 2Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 3Health News:Local Businesses Unite, Calling an End to Youth Homelessness 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 4Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 5Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 6Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 7Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 8Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 9Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 10Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 11
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)... , July 23, 2014  The management ... CBRX ) will hold a conference call on ... the second quarter ended June 30, 2014.  The ... 31, 2014Time: , 8:30 am EDTDial-in numbers: , ... or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... Global healthcare company GSK reports Q2 results ... price competition and supply disruptions to its Consumer business. ... out that the company is very much in transition, citing ... about long-term prospects as well as the investments being ... Simon Dingemans adds that the company is reining ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... Digital Pulse Oximeter monitors SpO2, ... It is designed to provide ... patients. The device rejects spontaneous ... the operator of excess artifacts ...
... The 8600FO is designed to ... MRI users for patient safety ... Fiber Optic Sensors and Cables ... is eliminated, as well as ...
... The 8600 Series Tabletop/Portable ... simple universal tool for patient ... continuous monitoring, the 8600 has ... professionals worldwide and is recognized ...
Medicine Products: